| 05/20 | Correction to Vir Biotechnology Shares Fall 9% Article | DJ |
| 05/20 | Vir Biotechnology Shares Fall 9% After Terminating Agreement with WuXi Bio | DJ |
| 05/20 | China stocks rise on higher-than-expected borrowing rate cut; foreign inflows surge | RE |
| 05/16 | South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies.. | MT |
| 05/16 | Samsung Biologics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 3.. | CI |
| 05/12 | Roche believes cancer drug setback not a fatal blow to growth prospects | RE |
| 05/11 | Hong Kong Stocks Rebound from Near Two-Month Low; Biotech Shares Rally | MT |
| 05/10 | Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D.. | MT |
| 05/09 | Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of.. | CI |
| 05/05 | Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait .. | MT |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T.. | CI |
| 05/04 | Michel Vounatsos to Step Down as Chief Executive Officer of Biogen | CI |
| 05/04 | Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating | MT |
| 05/04 | Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating | MT |
| 05/04 | RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating | MT |
| 05/04 | Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating | MT |
| 05/04 | Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Mainta.. | MT |
| 05/03 | Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020. | CI |
| 05/03 | Biogen's Quarterly Results Fall as Drugmaker Plans to Stop Selling Aduhelm; CEO to Step.. | MT |
| 05/03 | TIMELINE-Biogen CEO to leave as Alzheimer's drug struggles | RE |
| 05/03 | SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday | MT |
| 05/03 | Biogen Q1 Non-GAAP EPS, Revenue Drop; CEO Michel Vounatsos to Leave; Reaffirms 2022 Gui.. | MT |
| 05/03 | TRANSCRIPT : Biogen Inc., Q1 2022 Earnings Call, May 03, 2022 | CI |
| 05/03 | Biogen Inc. Reaffirms Revenue Guidance for the Full Year 2022 | CI |
| 05/03 | Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/03 | Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm | RE |
| 05/03 | Biogen quarterly profit falls 26% | RE |
| 05/02 | Biogen, Scribe Therapeutics Expand Research Collaboration to Second Disease Target | MT |
| 05/02 | Sage, Biogen Start Rolling Submission of New-Drug Application to US FDA for Major Depre.. | MT |
| 05/02 | Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application to U.S.. | CI |
| 04/28 | Wedbush Raises Biogen's Price Target to $188 From $185, Maintains Neutral Rating | MT |
| 04/28 | Eli Lilly obesity drug data shines, shares rise | RE |
| 04/28 | South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3% | MT |
| 04/28 | Samsung Biologics' Net Income Surges 141% in March Quarter | MT |
| 04/27 | Big Biotech Firms Have Several Catalysts Lined Up, UBS Says | MT |
| 04/27 | UBS Adjusts Biogen Price Target to $244 From $269, Maintains Buy Rating | MT |
| 04/22 | Biogen Withdraws European Marketing Authorization Application for Alzheimer's Disease D.. | MT |
| 04/22 | Biogen pulls application for Alzheimer's drug in Europe | RE |
| 04/22 | Biogen to withdraw Alzheimer's drug application in Europe | RE |
| 04/22 | Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm | DJ |
| 04/21 | SVB Leerink Adjusts Biogen Price Target to $270 From $300, Maintains Outperform Rating | MT |
| 04/20 | Samsung Biologics Co.,Ltd. completed the acquisition of the remaining 49.9% stake in Sa.. | CI |
| 04/18 | Wells Fargo Upgrades Biogen to Overweight From Equalweight; Adjusts Price Target to $26.. | MT |
| 04/12 | Barclays Adjusts Price Target for Biogen to $219 From $235, Maintains Equalweight Ratin.. | MT |
| 04/11 | Moody's Downgrades Biogen to Baa2 From Baa1; Outlook Negative | MT |
| 04/08 | TIMELINE-Alzheimer's drug from Biogen hits Medicare coverage curbs | RE |
| 04/08 | Needham Adjusts Biogen's Price Target to $262 form $290, Keeps Buy Rating | MT |
| 04/08 | SECTOR UPDATE : Health Care Stocks Edge Upward Premarket Friday | MT |
| 04/08 | SECTOR UPDATE : Health Care | MT |
| 04/08 | Oppenheimer Adjusts Biogen's Price Target to $240 From $285, Maintains Outperform Ratin.. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
